Nitisinone Capsule
FDA Label NDC 71863-119

23 label sections · Submitted to the FDA by Eton Pharmaceuticals, Inc. · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Eton Pharmaceuticals, Inc. for the product Nitisinone (NDC 71863-119). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding highlights of prescribing information these highlights do not include all the information needed to use nitisinone capsules safely and effectively. see full prescribing information for nitisinone capsules. nitisinone capsules, for oral use initial u.s. approval: 2002 1. indications and usage, 2.1 dosage, 2.2 administration instructions, 3. dosage forms and strengths, 4. contraindication, 5.1. elevated plasma tyrosine levels, ocular symptoms, developmental delay and hyperkeratotic plaques, 5.2. leukopenia and severe thrombocytopenia, 6.1 clinical trials experience, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

* Please review the disclaimer below.